Bucindolol Displays Intrinsic Sympathomimetic Activity in Human Myocardium

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Circulation

• Publication date

  2002-05-21

• Fields of study

  Medicine

• Identifiers
  DOI 10.1161/01.CIR.0000016050.79810.18PMID 12021232
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure.

  2001cited by this paper
• Characterization of β1‐selectivity, adrenoceptor‐Gs‐protein interaction and inverse agonism of nebivolol in human myocardium

  2001cited by this paper
• Effect of carvedilol on survival in severe chronic heart failure.

  2001cited by this paper
• A TRIAL OF THE BETA-BLOCKER BUCINDOLOL IN PATIENTS WITH ADVANCED CHRONIC HEART FAILURE

  2001cited by this paper
• A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure.

  2001cited by this paper
• Altered beta-adrenergic receptor gene regulation and signaling in chronic heart failure.

  2001cited by this paper
• Inverse agonism at heptahelical receptors: concept, experimental approach and therapeutic potential

  2000cited by this paper
• beta-adrenergic receptor blockade in chronic heart failure.

  2000cited by this paper
• Inhibition of Spontaneous β2-Adrenergic Activation Rescues β1-Adrenergic Contractile Response in Cardiomyocytes Overexpressing β2-Adrenoceptor*

  2000cited by this paper
• β-Adrenergic Receptor Blockade in Chronic Heart Failure

  2000cited by this paper
• Determinants of the cardiomyopathic phenotype in chimeric mice overexpressing cardiac Gsalpha.

  2000cited by this paper
• Different intrinsic activities of bucindolol, carvedilol and metoprolol in human failing myocardium

  2000cited by this paper
• Inhibition of spontaneous beta 2-adrenergic activation rescues beta 1-adrenergic contractile response in cardiomyocytes overexpressing beta 2-adrenoceptor.

  2000cited by this paper
• The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.

  1999cited by this paper
• Inverse agonist activities of beta-adrenoceptor antagonists in rat myocardium.

  1999cited by this paper
• Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)

  1999cited by this paper
• In vitro and in vivo characterization of intrinsic sympathomimetic activity in normal and heart failure rats.

  1999cited by this paper
• Opposing effects of beta(1)- and beta(2)-adrenergic receptors on cardiac myocyte apoptosis : role of a pertussis toxin-sensitive G protein.

  1999cited by this paper
• Opposing Effects of β1- and β2-Adrenergic Receptors on Cardiac Myocyte Apoptosis Role of a Pertussis Toxin–Sensitive G Protein

  1999cited by this paper
• Inverse agonist activities of β‐adrenoceptor antagonists in rat myocardium

  1999cited by this paper
• Evaluation of Intrinsic Sympathomimetic Activity of Bucindolol and Carvedilol in Rat Heart

  1998cited by this paper
• Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease

  1997cited by this paper
• Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Australia/New Zealand Heart Failure Research Collaborative Group.

  1997cited by this paper
• The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.

  1996cited by this paper
• Hemodynamic and energetic comparison of bucindolol and metoprolol for the treatment of congestive heart failure.

  1995cited by this paper
• Dose-response of chronic beta-blocker treatment in heart failure from either idiopathic dilated or ischemic cardiomyopathy. Bucindolol Investigators.

  1994cited by this paper
• Inverse agonist activity of beta-adrenergic antagonists.

  1994cited by this paper
• Altered expression of beta-adrenergic receptor kinase and beta 1-adrenergic receptors in the failing human heart.

  1993cited by this paper
• Quantitative reduction of MTT by hearts biopsies in vitro is an index of viability.

  1993cited by this paper
• Effects of bucindolol in heart failure.

  1993cited by this paper
• The xamoterol experience in the treatment of heart failure.

  1993cited by this paper
• Altered Expression of, ‐Adrenergic Receptor Kinase and 1‐Adrenergic Receptors in the Failing Human Heart

  1993cited by this paper
• Beta-blockade with bucindolol in heart failure caused by ischemic versus idiopathic dilated cardiomyopathy.

  1991cited by this paper
• Long-term (2 year) beneficial effects of beta-adrenergic blockade with bucindolol in patients with idiopathic dilated cardiomyopathy.

  1991cited by this paper
• β‐Blockade With Bucindolol in Heart Failure Caused by Ischemic Versus Idiopathic Dilated Cardiomyopathy

  1991cited by this paper
• Beta-adrenergic pathways in nonfailing and failing human ventricular myocardium.

  1990cited by this paper
• Effect of beta-adrenergic blockade on myocardial function and energetics in congestive heart failure. Improvements in hemodynamic, contractile, and diastolic performance with bucindolol.

  1990cited by this paper
• Mechanism of Action of Bucindolol in Human Ventricular Myocardium

  1990cited by this paper
• Increase of Gi alpha in human hearts with dilated but not ischemic cardiomyopathy.

  1990cited by this paper
• Xamoterol in severe heart failure.

  1990cited by this paper
• Long-term beta-blocker vasodilator therapy improves cardiac function in idiopathic dilated cardiomyopathy: a double-blind, randomized study of bucindolol versus placebo.

  1990cited by this paper
• Xamoterol in severe heart failure. The Xamoterol in Severe Heart Failure Study Group.

  1990cited by this paper
• Effect of bucindolol on plasma HDL cholesterol subfractions and other plasma lipids in essential hypertensive patients.

  1987cited by this paper
• Hemodynamic Effects During Rest and Exercise of Bucindolol in Hypertensive Men

  1987cited by this paper
• Efficacy of bucindolol in systemic hypertension.

  1987cited by this paper
• STUDIES ON THE VASODILATOR ACTIONS OF BUCINDOLOL IN THE RAT

  1986cited by this paper
• Bucindolol, a beta-adrenoceptor blocker with vasodilatory action: its effect in systemic hypertension.

  1984cited by this paper
• Beta-adrenoceptor and cardiovascular effects of MJ 13105 (bucindolol) in anesthetized dogs and rats.

  1980cited by this paper
• β-adrenoceptor and cardiovascular effects of MJ 13105 (Bucindolol) in anesthetized dogs and rats

  1980cited by this paper
• Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy.

  1975cited by this paper

• Beta-Blockers and Their Current Role in Maternal and Neonatal Health: A Narrative Review of the Literature

  2023cites this paper
• How carvedilol does not activate β2-adrenoceptors

  2023cites this paper
• Therapeutic Properties of Highly Selective β-blockers With or Without Additional Vasodilator Properties: Focus on Bisoprolol and Nebivolol in Patients With Cardiovascular Disease

  2021cites this paper
• Biased agonism at β-adrenergic receptors.

  2020cites this paper
• The Evolution of β-Blockers in Coronary Artery Disease and Heart Failure (Part 1/5).

  2019cites this paper
• Baker, Jillian G. and Kemp, Philip and March, Julie and Fretwell, Laurice and Hill, Stephen J. and Gardiner, Sheila M. (2011) Predicting in vivo cardiovascular properties of β-blockers from cellular assays: a quantative comparison of cellular and cardiovascular

  2016influential citation
• A Myocardial Slice Culture Model Reveals Alpha-1A-Adrenergic Receptor Signaling in the Human Heart

  2016cites this paper
• Pharmacogenomics of heart failure: a systematic review.

  2016cites this paper
• Overview of the therapy of heart failure due to systolic dysfunction

  2015cites this paper
• Sympathetic Nervous System Signaling in Heart Failure and Cardiac Aging

  2015cites this paper
• Reduced right ventricular ejection fraction and increased mortality in chronic systolic heart failure patients receiving β-blockers: insights from the BEST trial.

  2013cites this paper
• Association of &bgr;-Blocker Exposure With Outcomes in Heart Failure Differs Between African American and White Patients

  2012cites this paper
• Crystal Structures of a Stabilized β1-Adrenoceptor Bound to the Biased Agonists Bucindolol and Carvedilol

  2012cites this paper
• Association of Beta Blocker Exposure with Outcomes in Heart Failure Differs Between African American and White Patients Lanfear

  2012cites this paper
• Carvedilol

  2012cites this paper
• Contemporary medical management of systolic heart failure.

  2012cites this paper
• Predicting in vivo cardiovascular properties of β-blockers from cellular assays: a quantitative comparison of cellular and cardiovascular pharmacological responses

  2011influential citation
• Globalization of clinical trials how should we interpret differences in outcomes?

  2011cites this paper
• Hypertension and its management in countries in Africa and the Middle East, with special reference to the place of β-blockade

  2011cites this paper
• Pharmacogenomics of &bgr;-Adrenergic Receptor Physiology and Response to &bgr;-Blockade

  2011cites this paper
• Treatment of heart failure in African Americans--a call to action.

  2011cites this paper
• Review article Hypertension and its management in countries in Africa and the Middle East, with special reference to the place of b-blockade

  2011cites this paper
• Evolution of β-blockers: from anti-anginal drugs to ligand-directed signalling

  2011cites this paper
• Bucindolol: A Pharmacogenomic Perspective on Its Use in Chronic Heart Failure

  2011cites this paper
• Racial differences in heart failure therapeutics.

  2010cites this paper
• β-blockers in the treatment of dilated cardiomyopathy: which is the best?

  2010cites this paper
• [Advantages of vasodilating beta-blockers in congestive heart failure].

  2010cites this paper
• Role of β-blocker therapy in pediatric heart failure.

  2010cites this paper
• Intérêt des bêtabloquants vasodilatateurs dans l’insuffisance cardiaque

  2010cites this paper
• Heart Failure in Racial/Ethnic Groups

  2009cites this paper
• Race-based therapeutics

  2008cites this paper
• The low-affinity site of the beta1-adrenoceptor and its relevance to cardiovascular pharmacology.

  2008cites this paper
• Carvedilol in the treatment of elderly patients with chronic heart failure

  2008cites this paper
• Carvedilol in the treatment of chronic heart failure: Lessons from The Carvedilol Or Metoprolol European Trial

  2007cites this paper
• Beta-blocker therapy of heart failure: an update.

  2007cites this paper
• Are we misunderstanding beta-blockers.

  2007cites this paper
• β-adrenoceptor blocker treatment and the cardiac β-adrenoceptor-G-protein(s)-adenylyl cyclase system in chronic heart failure

  2007cites this paper
• Beta-adrenoceptor blocker treatment and the cardiac beta-adrenoceptor-G-protein(s)-adenylyl cyclase system in chronic heart failure.

  2007cites this paper
• β-blocker therapy of heart failure: an update

  2007cites this paper
• Race-based therapeutics

  2007cites this paper
• The evolution of heart failure management over recent decades: from CONSENSUS to CIBIS

  2006cites this paper
• Beta-blockade in CHF: from contraindication to indication

  2006cites this paper
• Overview of Beta Blockers for Systolic Heart Failure

  2006cites this paper
• A polymorphism within a conserved β1-adrenergic receptor motif alters cardiac function and β-blocker response in human heart failure

  2006cites this paper
• A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure.

  2006cites this paper
• Treatment of the african-american patient with congestive heart failure

  2005cites this paper
• Carvedilol Exerts More Potent Antiadrenergic Effect than Metoprolol in Heart Failure

  2005cites this paper
• Heart failure in African Americans.

  2005cites this paper
• beta-Blocker therapy for congestive heart failure: clinical considerations.

  2005cites this paper
• Beta-adrenergic receptors in heart failure.

  2005cites this paper
• β-Adrenergic Receptors in Heart Failure

  2005cites this paper
• New developments in the use of β-blockers for the management of heart failure

  2004cites this paper
• The prevention of heart failure in minority communities and discrepancies in health care delivery systems.

  2004cites this paper
• Beta-blockade in the management of systolic dysfunction.

  2004cites this paper
• Beta-Blockers in Heart Failure: Are Pharmacological Differences Clinically Important?

  2004cites this paper
• New developments in the use of beta-blockers for the management of heart failure.

  2004cites this paper
• Possible therapeutic targets in cardiac myocyte apoptosis.

  2004cites this paper
• Cardiomyopathy in muscular dystrophy workshop. 28-30 September 2003, Tucson, Arizona.

  2004cites this paper
• The use of beta-adrenergic receptor antagonists in the treatment of African Americans with heart failure.

  2004cites this paper
• Beta Blockers as Anti-Arrhythmic Agents

  2004cites this paper
• Heart failure in African Americans: pathophysiology and treatment.

  2003cites this paper
• Antiadrenergic Therapy of Chronic Heart Failure

  2003cites this paper
• Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials.

  2003cites this paper
• A comparative analysis of the results from 4 trials of beta-blocker therapy for heart failure: BEST, CIBIS-II, MERIT-HF, and COPERNICUS.

  2003cites this paper
• Can antiarrhythmic drugs save lives in patients with congestive heart failure?

  2003cites this paper
• Differential effects of carvedilol and atenolol on plasma noradrenaline during exercise in humans.

  2003cites this paper
• Beta-blockers after acute myocardial infarction in elderly patients with diabetes mellitus: time to reassess.

  2003cites this paper
• Therapeutics in Congestive Heart Failure: From Hemodynamics to Neurohormones

  2003cites this paper
• Expanding Role of β‐Blockade in the Management of Chronic Heart Failure

  2003cites this paper
• β-Blockers after Acute Myocardial Infarction in Elderly Patients with Diabetes Mellitus

  2003cites this paper
• Vasodilating β-adrenoceptor blockers as cardiovascular therapeutics

  2003cites this paper
• Vasodilating beta-adrenoceptor blockers as cardiovascular therapeutics.

  2003cites this paper
• Partial Agonist Activity of Bucindolol Is Dependent on the Activation State of the Human &bgr;1‐Adrenergic Receptor

  2003cites this paper
• Antiadrenergic therapy of chronic heart failure: surprises and new opportunities.

  2003cites this paper
• Expanding role of beta-blockade in the management of chronic heart failure.

  2003cites this paper
• Beta‐blocker benefit according to severity of heart failure

  2003cites this paper
• Beta-blockers in chronic heart failure: what have we learned? What do we still need to know?

  2003cites this paper
• Tolerability, safety, and efficacy of beta-blockade in black patients with heart failure in the community setting: insights from a large prospective beta-blocker registry.

  2003cites this paper
• Beta-blockers in chronic heart failure: considerations for selecting an agent.

  2002cites this paper